A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome

Current Medical Research and Opinion

Volumn 28, Issue 5, 2012, Pages 723-730

  Du, Qiang ^a   Wang, Yan Jun ^a   Yang, Sheng ^a   Wu, Bo ^a   Han, Ping ^a   Zhao, Yue Yang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Metformin; Pioglitazone; Polycystic ovary syndrome (PCOS); Systematic review

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; PIOGLITAZONE; TESTOSTERONE;

ANOREXIA; BODY MASS; CLINICAL ASSESSMENT TOOL; COMPARATIVE EFFECTIVENESS; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FERRIMAN GALLWEY SCORE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HOMOEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; META ANALYSIS; NAUSEA; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; TESTOSTERONE BLOOD LEVEL;

BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; HIRSUTISM; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; METFORMIN; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TESTOSTERONE; THIAZOLIDINEDIONES;

EID: 84861162349     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.681636     Document Type: Review

References (42)

1. Johnstone EB, Rosen MP, Neril R, et al. The Polycystic ovary post-Rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab 2010;95:4965-72
2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-61
3. Bhattacharya SM. Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions. Gynecol Endocrinol 2010;26:516-20
4. Moran LJ, Strauss BJ, Teede HJ. Diabetes risk score in the diagnostic categories of polycystic ovary syndrome. Fertil Steril 2011;95:1742-8
5. Toulis KA, Goulis DG, Kolibianakis EM, et al. Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Fertil Steril 2009;92:667-77
6. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010;95:2038-49
7. Phelan N, O'Connor A, Kyaw-Tun T, et al. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulinresistant women without PCOS. J Clin Endocrinol Metab 2010;95:3933-9
8. Luque-Ramrez M, Alpané s M, Escobar-Morreale HF. The determinants of insulin sensitivity,-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism. Fertil Steril 2010;94:2214-21
9. Wei HJ, Young R, Kuo IL, et al. Prevalence of insulin resistance and determination of risk factors for glucose intolerance in polycystic ovary syndrome: a cross-sectional study of Chinese infertility patients. Fertil Steril 2009; 91:1864-8
10. Kalra P, Bansal B, Nag P, et al. Abdominal fat distribution and insulin resistance in Indian women with polycystic ovarian syndrome. Fertil Steril 2009;91:1437-40
11. The practice Committee of the American Society for Reproductive Medicine. Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome. Fertil Steril 2004;82:S181-3
12. Koenen TB, Tack CJ, Kroese JM, et al. Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. J Clin Endocrinol Metab 2009;94:4453-57
13. Schoppee PD, Garmey JC, Veldhuis JD. Putative activation of the peroxisome proliferator-activated receptor g impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Biol Reprod 2002;66:190-8 (Pubitemid 34020603)
14. Bell DS, Ovalle F. Late-onset troglitazone-induced hepatic dysfunction. Diabetes Care 2000;23:128-9
15. FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm accessed 22 Febrary 2012.
16. Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2010;20:CD003053
17. Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007;13:527-37 (Pubitemid 350018522)
18. Costello MF, Eden JA. A systemic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1-13 (Pubitemid 36071228)
19. Naka KK, Kalantaridou SN, Kravariti M, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2011;95:203-9
20. Aroda VR, Ciaraldi TP, Burke P, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 2009;94:469-76
21. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009;6:e1000097
22. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7
23. Ortega-Gonzá lez C, Luna S, Herná ndez L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulinresistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;90:1360-5
24. Ortega-Gonzá lez C, Cardoza L, Coutino B, et al. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol 2005;184:233-9 (Pubitemid 40207577)
25. Naka KK, Kalantaridou SN, Kravariti M, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2011;95:203-9
26. Cho LW, Kilpatrick ES, Keevil BG, et al. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2009;70:233-7
27. Zhang N, Guo L, Lv C, et al. Comparison of clinical effects between pioglitazone and metformin plus Diane-35 on polycysfic ovary syndrome with insulin resistance. Prog Obstet Gynecol 2008;17:440-4
28. Lu S, Ma X-H, Shen J. On the ovulation effects in patients with polycystic ovary syndrome that one drug or in combination with others drugs. J Med Postgrad 2008;24:263-7
29. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19 (Pubitemid 15018832)
30. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7
31. Guyatt G, Vist G, Falck-Ytter Y, et al. An emerging consensus on grading recommendations? ACP J Club 2006;144:A8-9
32. Li XJ, Yu YX, Liu CQ, et al. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: A meta-analysis. Clin Endocrinol (Oxf);2011:74:332-9.
33. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003;115(Suppl 8A):42S-8S
34. Li XJ, Yu YX, Liu CQ, et al. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clin Endocrinol (Oxf) 2011;74:332-9
35. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;14:2457-71 (Pubitemid 46919772)
36. Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771:1065-81 (Pubitemid 47208546)
37. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201
38. Katsikis I, Karkanaki A, Misichronis G, et al. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011; 156:181-5
39. Olszanecka-Glinianowicz M, Kuglin D, Da? bkowska-Huć A, et al. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011;154:51-6
40. Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010; 94:2197-201
41. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63 (Pubitemid 30022895)
42. Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001;86:5457-64 (Pubitemid 33070275)